Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

868
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
868
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

656
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
656
Pneumonia IV: Management01:28

Pneumonia IV: Management

690
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
690
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.4K
The pathophysiology of pneumonia involves the following steps:
2.4K
Vaccinations01:51

Vaccinations

51.0K
Overview
51.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Maternal Vaccine Study Protocol: A Victorian Cohort Study Evaluating Infant and Childhood Safety and Health and Developmental Outcomes After Vaccination Against Respiratory Viruses in Pregnancy.

Vaccines·2026
Same author

Delayed diagnosis is associated with complications following invasive meningococcal disease in Australian adolescents and young adults.

Infection·2026
Same author

Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment.

Vaccine·2026
Same author

Characterizing thunderstorm asthma emergency department presentations using natural language processing for improved real-time surveillance.

American journal of epidemiology·2026
Same author

Clinical, psychological and quality of life outcomes up to 12-months following thrombosis with thrombocytopenia syndrome after ChAdOx1-S (AZD1222) vaccination in Australia.

Vaccine·2026
Same author

Incidence of Childhood Stroke and Association With Recent Infection: A Population-Based Study Using Linked Data.

Neurology·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
Same journal

Advancing lung transplantation: current challenges and future directions.

Current opinion in pulmonary medicine·2026
Same journal

Association between upper airway obstruction and pulmonary hypertension in children with Down syndrome.

Current opinion in pulmonary medicine·2026
Same journal

Molecular mechanisms of environmental risk factors for interstitial lung disease.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: Dec 30, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K

Vaccine development for capsulate bacteria causing pneumonia.

Fiona Mary Russell1, Jim Buttery

  • 1Centre for International Child Health, and Murdoch Childrens Research Institute, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Parkville, Melbourne, Australia.

Current Opinion in Pulmonary Medicine
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Pneumonia significantly impacts children and the elderly, with Streptococcus pneumoniae and Haemophilus influenzae type b being leading bacterial causes in children. Vaccines show promise, but further development is needed for widespread protection against pneumonia.

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.1K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

Related Experiment Videos

Last Updated: Dec 30, 2025

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.7K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.1K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Epidemiology

Background:

  • Pneumonia disproportionately affects children and the elderly, leading to significant mortality and disability globally.
  • Epidemiologic data on pneumonia incidence and causative agents remain limited.
  • Key bacterial pathogens include Streptococcus pneumoniae (SP), Haemophilus influenzae type b (Hib), and Group B Streptococcus (GBS).

Purpose of the Study:

  • To review the epidemiology of pneumonia, focusing on causative organisms and the impact of vaccines.
  • To highlight the role of Streptococcus pneumoniae, Haemophilus influenzae type b, and Group B Streptococcus in pediatric pneumonia.
  • To discuss the efficacy and limitations of current and developing vaccines.

Main Methods:

  • Literature review of epidemiologic data on pneumonia.
  • Analysis of causative agents in different age groups, particularly neonates and children.
  • Evaluation of vaccine efficacy and impact on disease incidence.

Main Results:

  • Streptococcus pneumoniae is the primary cause of bacterial pneumonia in children beyond the neonatal period.
  • Haemophilus influenzae type b and Streptococcus pneumoniae are leading causes in childhood; Hib vaccines prevent pneumonia in developing nations.
  • Group B Streptococcus remains a significant cause of neonatal sepsis and pneumonia.
  • SP conjugate vaccines show efficacy in low-incidence areas but offer marginal protection in high-incidence populations.
  • Non-vaccine SP serotypes have increased carriage but not invasive disease post-vaccination.
  • Group B Streptococcus vaccines are in early clinical development.

Conclusions:

  • Pneumonia remains a major global health challenge, especially for young children and the elderly.
  • Vaccination strategies, including Hib and SP conjugate vaccines, have impacted pneumonia incidence, though challenges remain.
  • Further development of vaccines, particularly for Group B Streptococcus, is crucial for reducing the burden of pneumonia.